Skip to content

Isoniazid preventive treatment reduces the risk of death by 37% in people living with HIV

Anani Badje at CROI 2017. Photo credit: Robb Cohen Photography & Video

Treatment or watchful waiting for cervical abnormalities in women with HIV?

Sharon Greene at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com

Tenofovir/emtricitabine/efavirenz less likely to cause adverse birth outcomes than other regimens, Botswana study finds

Rebecca Zash at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com

Experimental STI prophylaxis in PrEP users produces big drops in syphilis and chlamydia infections but not in gonorrhoea

Jean-Michel Molina at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com

Changes in viral suppression over time reveal disparities in HIV care in the United States

Nicole Crepaz at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com

Dual antiretroviral regimen maintains durable HIV suppression after switch

Josep Llibre at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com

Infants treated within days of birth can clear HIV reservoir rapidly

Louise Kuhn at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com

Treatment-as-prevention study sees substantial levels of transmitted drug resistance in participants, but no impact on treatment

Anne Derache at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com

Point-of-care test improves infant HIV diagnosis rate, treatment starts and retention in care

Ilesh Jani at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com